Addex partner indivior advances gabab positive allosteric modulator program successfully through ind enabling studies

Ad hoc announcement pursuant to art. 53 lr geneva, switzerland, may 12, 2025 - addex therapeutics (six/nasdaq: adxn), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today partner indivior has successfully advanced its gabab positive allosteric modulator (pam) program through ind enabling studies.
ADXN Ratings Summary
ADXN Quant Ranking